• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Differential analysis of RNA methylation regulators in gastric cancer based on TCGA data set and construction of a prognostic model.基于TCGA数据集的胃癌RNA甲基化调节因子差异分析及预后模型构建
J Gastrointest Oncol. 2021 Aug;12(4):1384-1397. doi: 10.21037/jgo-21-325.
2
m6A RNA methylation regulators play an important role in the prognosis of patients with testicular germ cell tumor.m6A RNA甲基化调节剂在睾丸生殖细胞肿瘤患者的预后中起重要作用。
Transl Androl Urol. 2021 Feb;10(2):662-679. doi: 10.21037/tau-20-963.
3
The m6A/m5C/m1A regulator genes signature reveals the prognosis and is related with immune microenvironment for hepatocellular carcinoma.m6A/m5C/m1A 调节基因标志物揭示了肝细胞癌的预后,并与免疫微环境相关。
BMC Gastroenterol. 2023 May 11;23(1):147. doi: 10.1186/s12876-023-02776-6.
4
The development and validation of a m6A-lncRNAs based prognostic model for overall survival in lung squamous cell carcinoma.基于m6A长链非编码RNA的肺鳞状细胞癌总生存预后模型的构建与验证
J Thorac Dis. 2022 Oct;14(10):4055-4072. doi: 10.21037/jtd-22-1185.
5
Estimating the prognosis of esophageal squamous cell carcinoma based on The Cancer Genome Atlas (TCGA) of m6A methylation-associated genes.基于癌症基因组图谱(TCGA)中m6A甲基化相关基因评估食管鳞状细胞癌的预后。
J Gastrointest Oncol. 2022 Feb;13(1):1-12. doi: 10.21037/jgo-21-686.
6
Exploration and validation of a combined Hypoxia and m6A/m5C/m1A regulated gene signature for prognosis prediction of liver cancer.缺氧和 m6A/m5C/m1A 调控基因特征的联合探索和验证用于肝癌预后预测。
BMC Genomics. 2023 Dec 14;24(1):776. doi: 10.1186/s12864-023-09876-3.
7
The Cancer Genome Atlas (TCGA) based m6A methylation-related genes predict prognosis in rectosigmoid cancer.基于癌症基因组图谱(TCGA)的 m6A 甲基化相关基因预测直肠乙状结肠癌的预后。
Medicine (Baltimore). 2022 Dec 23;101(51):e32328. doi: 10.1097/MD.0000000000032328.
8
Comprehensive Analysis of PD-L1 Expression, Immune Infiltrates, and m6A RNA Methylation Regulators in Esophageal Squamous Cell Carcinoma.食管鳞癌中 PD-L1 表达、免疫浸润与 m6A RNA 甲基化调控因子的综合分析
Front Immunol. 2021 May 12;12:669750. doi: 10.3389/fimmu.2021.669750. eCollection 2021.
9
Contributions and Prognostic Values of N6-Methyladenosine RNA Methylation Regulators in Hepatocellular Carcinoma.N6-甲基腺苷RNA甲基化调节因子在肝细胞癌中的作用及预后价值
Front Genet. 2021 Jan 15;11:614566. doi: 10.3389/fgene.2020.614566. eCollection 2020.
10
Novel methylation-related long non-coding RNA clinical outcome prediction method: the clinical phenotype and immune infiltration research in low-grade gliomas.新型甲基化相关长链非编码RNA临床结局预测方法:低级别胶质瘤的临床表型与免疫浸润研究
Front Oncol. 2023 May 9;13:1177120. doi: 10.3389/fonc.2023.1177120. eCollection 2023.

引用本文的文献

1
Targeting epigenetic regulators as a promising avenue to overcome cancer therapy resistance.将表观遗传调节因子作为克服癌症治疗耐药性的一条有前景的途径。
Signal Transduct Target Ther. 2025 Jul 18;10(1):219. doi: 10.1038/s41392-025-02266-z.
2
ALKBH3-regulated mA of ALDOA potentiates glycolysis and doxorubicin resistance of triple negative breast cancer cells.ALKBH3调控的醛缩酶A的N6-甲基腺嘌呤增强三阴性乳腺癌细胞的糖酵解和阿霉素耐药性。
Acta Pharm Sin B. 2025 Jun;15(6):3092-3106. doi: 10.1016/j.apsb.2025.04.018. Epub 2025 Apr 22.
3
Bioinformatics identification and validation of m6A/m1A/m5C/m7G/ac4 C-modified genes in oral squamous cell carcinoma.口腔鳞状细胞癌中m6A/m1A/m5C/m7G/ac4C修饰基因的生物信息学鉴定与验证
BMC Cancer. 2025 Jul 1;25(1):1055. doi: 10.1186/s12885-025-14216-7.
4
Role and mechanisms of m6A demethylases in digestive system tumors.m6A去甲基化酶在消化系统肿瘤中的作用及机制
Am J Cancer Res. 2025 Apr 15;15(4):1436-1460. doi: 10.62347/XMAF1290. eCollection 2025.
5
Targeting tRNA methyltransferases: from molecular mechanisms to drug discovery.靶向转运RNA甲基转移酶:从分子机制到药物研发
Sci China Life Sci. 2025 May 7. doi: 10.1007/s11427-024-2886-2.
6
Association between TRMT61B gene polymorphism and Wilms tumor susceptibility in Chinese children.TRMT61B基因多态性与中国儿童肾母细胞瘤易感性的关联
BMC Cancer. 2025 Feb 14;25(1):260. doi: 10.1186/s12885-025-13670-7.
7
The 7-Methylguanosine (m7G) methylation METTL1 acts as a potential biomarker of clear cell renal cell carcinoma progression.7-甲基鸟苷(m7G)甲基化的METTL1作为透明细胞肾细胞癌进展的潜在生物标志物。
Transl Oncol. 2025 Jan;51:102202. doi: 10.1016/j.tranon.2024.102202. Epub 2024 Nov 20.
8
Clinician's Guide to Epitranscriptomics: An Example of N-Methyladenosine (mA) RNA Modification and Cancer.表观转录组学临床医生指南:以N-甲基腺苷(m⁶A)RNA修饰与癌症为例
Life (Basel). 2024 Sep 25;14(10):1230. doi: 10.3390/life14101230.
9
RNA 5-Methylcytosine Modification: Regulatory Molecules, Biological Functions, and Human Diseases.RNA 5-甲基胞嘧啶修饰:调控分子、生物学功能及人类疾病
Genomics Proteomics Bioinformatics. 2024 Dec 3;22(5). doi: 10.1093/gpbjnl/qzae063.
10
Pan-cancer analysis of m1A writer gene RRP8: implications for immune infiltration and prognosis in human cancers.m1A书写基因RRP8的泛癌分析:对人类癌症免疫浸润和预后的影响
Discov Oncol. 2024 Sep 12;15(1):437. doi: 10.1007/s12672-024-01299-0.

本文引用的文献

1
A ten-gene methylation signature as a novel biomarker for improving prediction of prognosis and indicating gene targets in endometrial cancer.一种十基因甲基化特征作为改善子宫内膜癌预后预测和指示基因靶点的新型生物标志物。
Genomics. 2021 Jul;113(4):2032-2044. doi: 10.1016/j.ygeno.2021.04.035. Epub 2021 Apr 26.
2
The N -methyladenosine (m A) erasers alkylation repair homologue 5 (ALKBH5) and fat mass and obesity-associated protein (FTO) are prognostic biomarkers in patients with clear cell renal carcinoma.N6-甲基腺苷(m A)去甲基酶烷基化修复同源物 5(ALKBH5)和肥胖相关蛋白(FTO)是透明细胞肾细胞癌患者的预后生物标志物。
BJU Int. 2020 Apr;125(4):617-624. doi: 10.1111/bju.15019. Epub 2020 Feb 17.
3
NOP2/Sun RNA methyltransferase 2 promotes tumor progression via its interacting partner RPL6 in gallbladder carcinoma.NOP2/Sun RNA 甲基转移酶 2 通过其相互作用伙伴 RPL6 促进胆囊癌的肿瘤进展。
Cancer Sci. 2019 Nov;110(11):3510-3519. doi: 10.1111/cas.14190. Epub 2019 Sep 23.
4
RNA 5-Methylcytosine Facilitates the Maternal-to-Zygotic Transition by Preventing Maternal mRNA Decay.RNA 5-甲基胞嘧啶通过防止母体 mRNA 降解促进母源到合子的过渡。
Mol Cell. 2019 Sep 19;75(6):1188-1202.e11. doi: 10.1016/j.molcel.2019.06.033. Epub 2019 Aug 6.
5
5-methylcytosine promotes pathogenesis of bladder cancer through stabilizing mRNAs.5-甲基胞嘧啶通过稳定 mRNA 促进膀胱癌的发病机制。
Nat Cell Biol. 2019 Aug;21(8):978-990. doi: 10.1038/s41556-019-0361-y. Epub 2019 Jul 29.
6
ALKBH5 promotes invasion and metastasis of gastric cancer by decreasing methylation of the lncRNA NEAT1.ALKBH5 通过降低 lncRNA NEAT1 的甲基化促进胃癌的侵袭和转移。
J Physiol Biochem. 2019 Aug;75(3):379-389. doi: 10.1007/s13105-019-00690-8. Epub 2019 Jul 9.
7
Epidrugs: targeting epigenetic marks in cancer treatment.表观遗传学药物:癌症治疗中的靶向表观遗传标记。
Epigenetics. 2019 Dec;14(12):1164-1176. doi: 10.1080/15592294.2019.1640546. Epub 2019 Jul 13.
8
mA mRNA demethylase FTO regulates melanoma tumorigenicity and response to anti-PD-1 blockade.mA mRNA 去甲基酶 FTO 调控黑色素瘤的肿瘤发生和对抗 PD-1 封锁的反应。
Nat Commun. 2019 Jun 25;10(1):2782. doi: 10.1038/s41467-019-10669-0.
9
Silencing long non-coding RNA HOTAIR exerts anti-oncogenic effect on human acute myeloid leukemia via demethylation of HOXA5 by inhibiting Dnmt3b.沉默长链非编码RNA HOTAIR通过抑制Dnmt3b使HOXA5去甲基化,从而对人类急性髓系白血病发挥抗癌作用。
Cancer Cell Int. 2019 Apr 29;19:114. doi: 10.1186/s12935-019-0808-z. eCollection 2019.
10
Emerging approaches for detection of methylation sites in RNA.RNA 甲基化位点检测的新方法。
Open Biol. 2018 Sep;8(9). doi: 10.1098/rsob.180121.

基于TCGA数据集的胃癌RNA甲基化调节因子差异分析及预后模型构建

Differential analysis of RNA methylation regulators in gastric cancer based on TCGA data set and construction of a prognostic model.

作者信息

Li Jing, Zuo Zhifan, Lai Shusheng, Zheng Zhendong, Liu Bo, Wei Yuan, Han Tao

机构信息

Key Laboratory of Visceral Theory and Application in Traditional Chinese Medicine of Ministry of Education, Liaoning University of Traditional Chinese Medicine, Shenyang, China.

China Medical University, The General Hospital of Northern Theater Command Training Base for Graduate, Shenyang, China.

出版信息

J Gastrointest Oncol. 2021 Aug;12(4):1384-1397. doi: 10.21037/jgo-21-325.

DOI:10.21037/jgo-21-325
PMID:34532096
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8421903/
Abstract

BACKGROUND

Methylation is one of the common forms of RNA modification, which mainly include N6-methyladenosine (m6A), C5-methylcytidine (m5C), and N1-methyladenosine (m1A). Numerous studies have shown that RNA methylation is associated with tumor development. We aim to construct prognostic models of gastric cancer based on RNA methylation regulators.

METHODS

The transcriptome and clinical data of gastric cancer and normal samples were obtained from the National Cancer Institute Genome Data Commons (NCI-GDC). Use Least Absolute Shrinkage and Selection Operator (LASSO) Cox regression analysis to construct risk models for different types of RNA methylation. Receiver operating characteristic (ROC) curves were generated to evaluate the predictive efficiency of risk characteristics. Cluster heat maps are used to assess the correlation with clinical information. Univariate and multivariate Cox analyses were used to analyze prognostic effects of risk scores. Gene Set Enrichment Analysis (GSEA) analyzes the functional enrichment of RNA methylation genes. And make a separate analysis of the data of Asians.

RESULTS

The expression of most of the 30 RNA methylation regulators were significantly different in cancer and paracancerous tissues (P<0.05). Three methylated genes (, , and ) were screened from m6A by LASSO Cox regression analysis. Five methylated genes (, , , , and ) were selected from the population, and were used to construct two risk ratio models. Survival analysis showed that the survival rate of patients in the low-risk group was significantly higher than that in the high-risk group (P<0.05). All ROC curves indicated that the predictive efficiency of risk characteristics was good [area under the ROC curve (AUC): 0.6-1].Cluster analysis reveals differences in clinical data between the two groups. Univariate and multivariate Cox regression results show that the risk score has independent prognostic value. GSEA showed that pathways such as cell cycle were significantly enriched in the low-risk group, while pathways such as calcium signaling pathway were significantly enriched in the high-risk group. In addition, three methylation models that can predict the prognosis of Asian gastric cancer patients were obtained.

CONCLUSIONS

The methylation prognosis model constructed in this study can effectively predict the prognosis of gastric cancer patients.

摘要

背景

甲基化是RNA修饰的常见形式之一,主要包括N6-甲基腺苷(m6A)、C5-甲基胞嘧啶(m5C)和N1-甲基腺苷(m1A)。大量研究表明,RNA甲基化与肿瘤发展相关。我们旨在构建基于RNA甲基化调节因子的胃癌预后模型。

方法

从美国国立癌症研究所基因组数据共享库(NCI-GDC)获取胃癌及正常样本的转录组和临床数据。使用最小绝对收缩和选择算子(LASSO)Cox回归分析构建不同类型RNA甲基化的风险模型。生成受试者工作特征(ROC)曲线以评估风险特征的预测效率。聚类热图用于评估与临床信息的相关性。单因素和多因素Cox分析用于分析风险评分的预后效应。基因集富集分析(GSEA)分析RNA甲基化基因的功能富集情况。并对亚洲人的数据进行单独分析。

结果

30个RNA甲基化调节因子中的大多数在癌组织和癌旁组织中的表达存在显著差异(P<0.05)。通过LASSO Cox回归分析从m6A中筛选出3个甲基化基因( 、 和 )。从总体中选出5个甲基化基因( 、 、 、 和 ),并用于构建两个风险比模型。生存分析表明,低风险组患者的生存率显著高于高风险组(P<0.05)。所有ROC曲线均表明风险特征的预测效率良好[ROC曲线下面积(AUC):0.6 - 1]。聚类分析揭示了两组临床数据的差异。单因素和多因素Cox回归结果表明,风险评分具有独立的预后价值。GSEA显示,细胞周期等通路在低风险组中显著富集,而钙信号通路等通路在高风险组中显著富集。此外,获得了3个可预测亚洲胃癌患者预后的甲基化模型。

结论

本研究构建的甲基化预后模型可有效预测胃癌患者的预后。